<?xml version="1.0" encoding="UTF-8"?>
<ref id="B94">
 <label>94.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Agnandji</surname>
    <given-names>ST</given-names>
   </name>
   <name>
    <surname>Huttner</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Zinser</surname>
    <given-names>ME</given-names>
   </name>
   <name>
    <surname>Njuguna</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Dahlke</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Fernandes</surname>
    <given-names>JF</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Phase 1 trials of rVSV Ebola vaccine in Africa and Europe</article-title>. 
  <source>N Engl J Med</source>. (
  <year>2016</year>) 
  <volume>374</volume>:
  <fpage>1647</fpage>â€“
  <lpage>60</lpage>. 
  <pub-id pub-id-type="doi">10.1056/NEJMoa1502924</pub-id>
  <?supplied-pmid 25830326?>
  <pub-id pub-id-type="pmid">25830326</pub-id>
 </mixed-citation>
</ref>
